THE PURPOSE OF THIS AGREEMENT IS TO FUND RESEARCH SUPPORTING THE DEFENSE ADVANCED RESEARCH PROJECTS AGENCY DARPA CORNERSTONE PROGRAM. THIS EFFORT SHALL BE CARRIED OUT GENERALLY AS SET FORTH IN EXHIBIT B, RESEARCH DESCRIPTION DOCUMENT, DATED FEBRUARY 20, 2024, AND IN THE RECIPIENTS PROPOSAL TITLED, BRIVARACETAM AN SV2A LIGAND ANTISEIZURE DRUG FOR NEUROPROTECTIVE PROPHYLAXIS AGAINST TRAUMATIC BRAIN INJURY, DATED APRIL 20, 2023, COPIES OF WHICH ARE IN THE POSSESSION OF BOTH PARTIES.